8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Morris Douglas
9
- - Clinical Protocol Design
- - 6 weeks April - May 2023
- - Pharmaceutical Company
Reviewed:
Comprehensive protocol design, very detailed and precise.
The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.
Allen Kunde Jr.
8.9
- - Stability Studies
- - 18 months January 2023 - June 2024
- - Pharmaceutical Company
Reviewed:
Accurate and reliable stability studies, clear reporting.
The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.
Marion Boehm PhD
9.1
- - Pharmacovigilance Services
- - Ongoing
- - Pharmaceutical Company
Reviewed:
Highly effective pharmacovigilance services, ensured compliance.
The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.
Laura Blick
9
- - Biomarker Development
- - 12 weeks October 2023 - January 2024
- - Research Institution
Reviewed:
Efficient and precise biomarker development.
The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.
Ms. Shari Okuneva
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
Paul Jones
9.3
- - Project Management
- - 10 weeks July - September 2023
- - Biotech Company
Reviewed:
Seamless project management, results exceeded expectations.
Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.
April Witting IV
9.4
- - Health Technology Assessment
- - 10 weeks September - November 2023
- - Pharmaceutical Company
Reviewed:
Thorough and insightful health technology assessment.
The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.
Francis Ebert
8.8
- - Companion Diagnostics Development
- - 16 weeks January - May 2024
- - Pharmaceutical Company
Reviewed:
High-quality companion diagnostics development, delivered on time.
The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.
